Literature DB >> 19464285

Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.

Gongliang Zhang1, Swapna Krishnamoorthy, Zhiyuan Ma, Nick P Vukovich, Xupei Huang, Rui Tao.   

Abstract

Serotonin (5-hydroxytryptamine; 5-HT)-toxicity syndrome, an iatrogenic brain disorder induced by excessive efflux of 5-HT, has received much attention because of increasing incidents of serotonergic antidepressants. However, the neural mechanism by which extracellular 5-HT is elevated to a toxic level for the syndrome remains to be determined. The goal of the present study was to test the hypothesis that extracellular 5-HT is composed of two component effluxes responsible for distinct aspects of the syndrome. The first set of experiments was to characterize the syndrome by measuring changes in neuromuscular signs, body-core temperature and mortality rate. Our results indicate that the syndrome severity can be categorized into mild, moderate and severe levels. The second set of experiments was to determine a threshold of extracellular 5-HT for induction of each level of the syndrome. Our results demonstrate that there were an 11-fold increase in the mild syndrome and an over 55-fold increase in the severe syndrome. In the last series of experiments, the excessive increases in 5-HT were pharmacologically separated into primary and secondary component effluxes with the 5-HT2A receptor antagonists cyproheptadine and ketanserin and NMDA receptor antagonist (+)-MK-801. Our results suggest that the primary component efflux was caused by direct drug effects on 5-HT biosynthetic and metabolic pathways and secondary efflux ascribed to indirect drug effect on a positive-feedback circuit involving 5-HT2A and NMDA receptors. In summary, the primary efflux could be an initial cause for the induction of the syndrome while the secondary efflux might involve deterioration of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464285      PMCID: PMC2756783          DOI: 10.1016/j.ejphar.2009.05.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  51 in total

1.  Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism.

Authors:  R Martín-Ruiz; M V Puig; P Celada; D A Shapiro; B L Roth; G Mengod; F Artigas
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.

Authors:  K Nisijima; T Yoshino; K Yui; S Katoh
Journal:  Brain Res       Date:  2001-01-26       Impact factor: 3.252

3.  Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus.

Authors:  K J Damjanoska; L D Van de Kar; G H Kindel; Y Zhang; D N D'Souza; F Garcia; G Battaglia; N A Muma
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

4.  In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents.

Authors:  M Victoria Puig; Pau Celada; Llorenç Díaz-Mataix; Francesc Artigas
Journal:  Cereb Cortex       Date:  2003-08       Impact factor: 5.357

5.  Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study.

Authors:  R Zanardi; F Artigas; R Moresco; C Colombo; C Messa; C Gobbo; E Smeraldi; F Fazio
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

6.  Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.

Authors:  I Hervás; C M Queiroz; A Adell; F Artigas
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

7.  Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats.

Authors:  F Borsini; A Brambilla; R Cesana; N Grippa
Journal:  Int J Neuropsychopharmacol       Date:  2001-03       Impact factor: 5.176

8.  Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.

Authors:  M J Millan; J M Rivet; H Canton; S Le Marouille-Girardon; A Gobert
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

9.  Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.

Authors:  Zhiyuan Ma; Gongliang Zhang; Chris Jenney; Swapna Krishnamoorthy; Rui Tao
Journal:  Eur J Pharmacol       Date:  2008-04-08       Impact factor: 4.432

10.  Long-lasting effects of chronic stress on DOI-induced hyperthermia in male rats.

Authors:  Leslie Matuszewich; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

View more
  6 in total

1.  Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan
Journal:  Ann Forensic Res Anal       Date:  2017-03-07

2.  Mechanisms and environmental factors that underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan; H Daniel Adams; Zhiyuan Ma
Journal:  Psychopharmacology (Berl)       Date:  2014-10-11       Impact factor: 4.530

3.  Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers.

Authors:  Rui Tao; Mary Rudacille; Gongliang Zhang; Zhiyuan Ma
Journal:  Neuropsychopharmacology       Date:  2014-02-28       Impact factor: 7.853

4.  Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.

Authors:  M A Fox; M G Panessiti; P R Moya; T J Tolliver; K Chen; J C Shih; D L Murphy
Journal:  Pharmacogenomics J       Date:  2012-09-11       Impact factor: 3.550

5.  Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats.

Authors:  Zhiyuan Ma; Mary Rudacille; Howard M Prentice; Rui Tao
Journal:  J Neurochem       Date:  2013-01-28       Impact factor: 5.372

6.  New Insights on Different Response of MDMA-Elicited Serotonin Syndrome to Systemic and Intracranial Administrations in the Rat Brain.

Authors:  Ibrahim M Shokry; John J Callanan; John Sousa; Rui Tao
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.